Literature DB >> 31995406

Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study.

Idir Hamdidouche1, Philippe Gosse2, Antoine Cremer, Aurelien Lorthioir3, Pascal Delsart4, Pierre-Yves Courand5,6, Thierry Denolle7, Jean-Michel Halimi8, Xavier Girerd9, Olivier Ormezzano10, Patrick Rossignol11, Helena Pereira1,3,12, Michel Azizi1,3,13.   

Abstract

Clinic-ambulatory blood pressure (BP) difference is influenced by patients- and device-related factors and inadequate clinic-BP measurement. We investigated whether nonadherence to antihypertensive medications may also influence this difference in a post hoc analysis of the DENERHTN trial (Renal Denervation for Hypertension). We pooled the data of 77 out of 106 evaluable patients with apparent resistant hypertension who received a standardized antihypertensive treatment and had both ambulatory BP and drug-screening results available at baseline after 1 month of standardized triple therapy and at 6 months on a median of 5 antihypertensive drugs. After drug assay samplings on study visits, patients took their antihypertensive treatment under supervision immediately after the start of the ambulatory BP recording, and supine clinic BP was measured 24 hours post-dosing; both allowed to calculate the clinic minus daytime ambulatory systolic BP (SBP) difference (clinic-SBP-day-SBP). A total of 29 (37.7%) were found nonadherent to medications at baseline and 38 (49.4%) at 6 months. At baseline, the mean clinic-SBP-day-SBP difference in the nonadherent group was 12.7 mm Hg (95% CI, 7.8-17.7 mm Hg, P<0.001). In contrast, clinic SBP was almost identical to day-SBP in the adherent group (clinic-SBP-day-SBP difference, 0.1 mm Hg; 95% CI, -3.3 to 3.5 mm Hg; P=0.947). Similar observations were made at 6 months. Using receiver operating characteristics curves, we found that a 6 mm Hg cutoff of clinic-SBP-day-SBP difference had 67% sensitivity and 69% specificity to predict nonadherence to the triple therapy at baseline. In conclusion, a large clinic-SBP-day-SBP difference may help discriminating between adherence and nonadherence to treatment in patients with resistant hypertension. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01570777.

Entities:  

Keywords:  blood pressure; hypertension; medication adherence; renal denervation

Year:  2019        PMID: 31995406     DOI: 10.1161/HYPERTENSIONAHA.119.13520

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  3 in total

Review 1.  Renal denervation for resistant hypertension.

Authors:  Anna Pisano; Luigi Francesco Iannone; Antonio Leo; Emilio Russo; Giuseppe Coppolino; Davide Bolignano
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

2.  Predicting medication nonadherence risk in the Chinese type 2 diabetes mellitus population - establishment of a new risk nomogram model: a retrospective study.

Authors:  Fa-Cai Wang; Wei Chang; Song-Liu Nie; Bing-Xiang Shen; Chun-Yuan He; Wei-Chen Zhao; Xiao-Yan Liu; Jing-Tao Lu
Journal:  J Int Med Res       Date:  2021-09       Impact factor: 1.671

3.  Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease-A Report from the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Jesse Felts; Carolyn S Brecklin; Jing Chen; Paul E Drawz; Eva Lustigova; Rupal Mehta; Edgar R Miller; Stephen M Sozio; Matthew R Weir; Dawei Xie; Xue Wang; Mahboob Rahman
Journal:  Kidney360       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.